For PatientsPrescribing Information Important Safety Information
For US Healthcare
Professionals
ONCASPAR (pegaspargase) is indicated as a component of multi-agent chemotherapeutic regimen for treatment of patients with:
  • First-line acute lymphoblastic leukemia (ALL)
  • ALL and hypersensitivity to native forms of L-asparaginase
 
Important Safety Information
ONCASPAR® should not be given to people who have had:
  • History of serious allergic reactions to ONCASPAR
  • History of serious thrombosis with prior L-asparaginase therapy
  • History of pancreatitis with prior L-asparaginase therapy
  • History of serious hemorrhagic events with prior L-asparaginase therapy

See Full Important Safety Information

ONCASPAR HomeAbout ONCASPARONCASPAR in ALLPatient ProfilesEfficacySafetyDosing and AdministrationResources and Support
ONCASPAR HomeAbout ONCASPARONCASPAR in ALLPatient ProfilesEfficacySafetyDosing and AdministrationResources and Support
PharmacokineticsTherapeutic Activity LevelsSustained Asparagine Depletion
A single dose of ONCASPAR® (pegaspargase) delivered sustained levels of asparaginase activity2,4
  • Normal cells can produce asparagine, but some lymphoblastic leukemic cells cannot1,3
  • Depletion of L-asparagine in blood serum results in inhibition of protein sythesis, DNA-synthesis, and RNA-synthesis1
  • Normal cells are capable of synthesizing L-asparagine and are less affected by its rapid withdrawal during treatment with the enzyme L-asparaginase1
ONCASPAR (a pegylated asparaginase) offered sustained asparaginase activity with a single dose5

Comparative pharmacokinetic (PK) study of asparaginase concentration over time5Serum asparaginase concentration
Values are mean ± SD. Each line represents the linear regression analysis for a group.
Study Design
The half-life of different formulations of asparaginase was determined in newly diagnosed patients with ALL. In a PK evaluation, children with newly diagnosed ALL were treated with 2 sequential protocols. Between 1985 and 1987, patients were randomized to receive E. coli asparaginase 25,000 IU/m2 as a single intramuscular injection or 2500 IU/m2 as a single intramuscular injection on the first day of therapy. Between 1987 and 1991, patients were randomized to receive native E. coli asparaginase 25,000 IU/m2, Erwinia asparaginase 25,000 IU/m2, or ONCASPAR 2500 IU/m2. Asparaginase activity was measured using spectrophotometric assay from serum samples of patients.5
Indication and Usage

ONCASPAR (pegaspargase) is indicated as a component of multi-agent chemotherapeutic regimen for treatment of patients with:
• First-line acute lymphoblastic leukemia (ALL)
• ALL and hypersensitivity to native forms of L-asparaginase

Detailed Important Safety Information
CONTRAINDICATIONS
• History of serious allergic reactions to ONCASPAR
• History of serious thrombosis with prior L-asparaginase therapy
• History of pancreatitis with prior L-asparaginase therapy
• History of serious hemorrhagic events with prior L-asparaginase therapy

WARNINGS and PRECAUTIONS
Anaphylaxis and Serious Allergic Reactions: Anaphylaxis or serious allergic reactions can occur; therefore, patients should be observed for one hour after administration. Discontinue ONCASPAR in patients with serious allergic reactions.
Thrombosis: Serious thrombotic events, including sagittal sinus thrombosis can occur. Discontinue ONCASPAR in patients with serious thrombotic events.
Pancreatitis: Pancreatitis can occur. Evaluate patients with abdominal pain for evidence of pancreatitis. Discontinue ONCASPAR in patients with pancreatitis.
Glucose Intolerance: Glucose intolerance can occur. In some cases, glucose intolerance is irreversible. Monitor serum glucose.
Coagulopathy: Increased prothrombin time, increased partial thromboplastin time, and hypofibrinogenemia can occur. Monitor coagulation parameters at baseline and periodically during and after treatment.
Hepatotoxicity: Hepatotoxicity and abnormal liver function can occur. Perform appropriate monitoring.

ADVERSE REACTIONS

The most common adverse reactions with ONCASPAR (≥2%) are allergic reactions (including anaphylaxis), hyperglycemia, pancreatitis, central nervous system (CNS) thrombosis, coagulopathy, hyperbilirubinemia, and elevated transaminases.
Hyperlipidemia (hypercholesterolemia and hypertriglyceridemia) has been reported in patients exposed to ONCASPAR.
Please click here for Full Prescribing Information.

All content on this website, including text, images, graphics, sound files, and their arrangement, is copyrighted and owned by Shire and is protected by international copyright laws. All other intellectual property rights are reserved. The content may not be copied for commercial use or distribution, nor may these objects be downloaded, modified, or posted to other sites.

This site is intended solely for US residents and is governed solely by US laws and government regulations. Please see our Legal Notice for more information. While Shire US Inc. makes reasonable efforts to include accurate, up-to-date information on this site, Shire US Inc. makes no warranties or representations as to its accuracy. Shire US Inc. assumes no liability for any errors or omissions in the content of this site.

Shire Logo

Privacy Notice   Legal Disclaimers     Shire Corporate Website     Contact Us     ONCASPAR Order Form       References     

©2018 Shire US Inc., Lexington, MA 02421. All rights reserved. 1-800-828-2088. SHIRE and the Shire logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates. ONCASPAR is a registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.
S34210 07/18

Menu
ONCASPAR Home
Indication and Usage
ONCASPAR (pegaspargase) is indicated as a component of multi-agent chemotherapeutic regimen for treatment of patients with:
Detailed Important Safety Information
CONTRAINDICATIONS
WARNINGS and PRECAUTIONS
Anaphylaxis and Serious Allergic Reactions: Anaphylaxis or serious allergic reactions can occur; therefore, patients should be observed for one hour after administration. Discontinue ONCASPAR in patients with serious allergic reactions.
Thrombosis: Serious thrombotic events, including sagittal sinus thrombosis can occur. Discontinue ONCASPAR in patients with serious thrombotic events.
Pancreatitis: Pancreatitis can occur. Evaluate patients with abdominal pain for evidence of pancreatitis. Discontinue ONCASPAR in patients with pancreatitis.
Glucose Intolerance: Glucose intolerance can occur. In some cases, glucose intolerance is irreversible. Monitor serum glucose.
Coagulopathy: Increased prothrombin time, increased partial thromboplastin time, and hypofibrinogenemia can occur. Monitor coagulation parameters at baseline and periodically during and after treatment.
Hepatotoxicity: Hepatotoxicity and abnormal liver function can occur. Perform appropriate monitoring.
ADVERSE REACTIONS

The most common adverse reactions with ONCASPAR (≥2%) are allergic reactions (including anaphylaxis), hyperglycemia, pancreatitis, central nervous system (CNS) thrombosis, coagulopathy, hyperbilirubinemia, and elevated transaminases.
Hyperlipidemia (hypercholesterolemia and hypertriglyceridemia) has been reported in patients exposed to ONCASPAR.
Please click here for Full Prescribing Information.

All content on this website, including text, images, graphics, sound files, and their arrangement, is copyrighted and owned by Shire and is protected by international copyright laws. All other intellectual property rights are reserved. The content may not be copied for commercial use or distribution, nor may these objects be downloaded, modified, or posted to other sites.

This site is intended solely for US residents and is governed solely by US laws and government regulations. Please see our Legal Notice for more information. While Shire US Inc. makes reasonable efforts to include accurate, up-to-date information on this site, Shire US Inc. makes no warranties or representations as to its accuracy. Shire US Inc. assumes no liability for any errors or omissions in the content of this site.

Shire Logo
Privacy Notice
Legal Disclaimers
Shire Corporate Website
ONCASPAR Order Form
Contact Us
References

©2018 Shire US Inc., Lexington, MA 02421. All rights reserved. 1-800-828-2088. SHIRE and the Shire logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates. ONCASPAR is a registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.
S34210 07/18